Current Edition

Pricing pharmaceuticals in Japan
Volume 11 Issue 1

Pricing Pharmaceuticals in Japan

The year 2018 was epic for the Japanese pharmaceutical industry, largely because of the fundamental National Health Insurance (NHI) pricing reforms implemented in April, says …

Continue Reading →
Why companies need to act now to
Volume 11 Issue 1

Why Companies Need to Act Now to Guarantee EU Medical Device Regulation Compliance

There are just over 12 months to go until the EU Medical Device Regulation (MDR) enforcement deadline of May 2020. This is driving major efforts …

Continue Reading →
The impact of a no-deal Brexit
Volume 11 Issue 1

The Impact of a No-deal Brexit on Pharmaceutical Patents – The Main Considerations

In this article, Jim Robertson at Wynne Jones IP discusses how uncertainty surrounding a potential no-deal Brexit has created a deep chasm in opinion in …

Continue Reading →
The manufacturing-regulatory data
Volume 11 Issue 1

The Manufacturing-regulatory Data Continuum: Forging New Connections

It makes no sense that product data exists separately in ERP and RIM systems, compromising any efforts to improve efficiency through tighter inter-function collaboration. A …

Continue Reading →
Are your companion diagnostic
Volume 11 Issue 1

Are your Companion Diagnostic Partners Ready?

The new In Vitro Diagnostic Medical Devices Regulation (IVDR), EU 2017/746, was published in the Official Journal of the European Union in May 2017 with …

Continue Reading →
How modular content delivers
Volume 11 Issue 1

How Modular Content Delivers Personalised Life Sciences Engagement

The rise of digital impacts the life sciences industry in multiple ways, says Emma Hyland at VEEVA. When it comes to content, it is fundamentally …

Continue Reading →
Driving patient engagement
Volume 11 Issue 1

Driving Patient Engagement with Serialisation Data and mHealth

Businesses throughout the pharmaceutical supply chain can now develop collaborative solutions that will fundamentally change the way the industry shares information. The potential to provide …

Continue Reading →
Comparing genetic modification
Volume 11 Issue 1

Comparing Genetic Modification Techniques for Animal Model Generation

The first germline transmission-capable transgenic mice were developed in the early 1980s in the laboratories of Frank Ruddle (Yale), Ralph Brinster (University of Pennsylvania), and …

Continue Reading →
Highly potent molecules
Volume 11 Issue 1

Highly Potent Molecules: Safe, Effective Processing

The pharmaceutical landscape continues to evolve, with much R&D focusing on more specialised medicines. As the biological activity and specificity of the API increases, dosage …

Continue Reading →
Cell disruption equipment selection
Volume 11 Issue 1

Cell Disruption Equipment Selection – Making the Optimal Choice Technically and Financially

There are several methods for achieving cell disruption; however, high-pressure homogenisation (HPH) / microfluidisation is the standard approach for the scale of this client’s microbiological …

Continue Reading →